Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin®) for AMD followed by controlateral sympathetic ophthalmia

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 457-459

  Brouzas, Dimitrios ^a   Koutsandrea, Chryssanthi ^a   Moschos, Marilita ^a   Papadimitriou, Spiros ^a   Ladas, Ioannis ^a   Apostolopoulos, Michael ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Avastin complication; Choroidal detachment; Intravitreal injection; Phthisis bulbi; Sympathetic ophthalmia

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; METOPROLOL TARTRATE; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CASE REPORT; CHOROID HEMORRHAGE; CLINICAL FEATURE; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; MALE; RETINA MACULA AGE RELATED DEGENERATION; SCLEROTOMY; SYMPATHETIC OPHTHALMIA; VALVE;

EID: 77953463229     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s4641     Document Type: Article

References (14)

1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
2. Avery RL, Pieramici D, Rabena M, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
3. Spaide R, Laud K, Fine H, et al. Treatment of chroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26: 383-390.
4. Avery R. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352-353.
5. Davidorf F, Mouser G, Derick R. Rapid improvement of rubeosis iridis from a single Bevacizumab (Avastin) injection. Retina. 2006;26:354-356.
6. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol. 2005;243:734-736.
7. Jonas JB, Spandau UH. Repeated Intravitreal triamcinolone acetonide for chronic sympathetic ophthalmia. Acta Ophthalmol Scand. 2006;84:436.
8. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
9. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006;5: 553-566.
10. Nicolò M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol. 2006;16:770-773.
11. Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol. 2006;142:1070-1072.
12. Kook D, Wolf A, Neubauer AS, et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologie. 2008;105:158-164.
13. Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative macular degeneration. Clin Experiment Ophthalmol. 2008;36:252-256.
14. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU. Intravitreal bevacizumab for shoroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47:4569-4578.